Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1645 1646
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Non-Final OA | NOVARTIS AG |
| 18280970 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF MYASTHENIA GRAVIS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18531168 | TARGETING ANTI-HUMAN PD 1H/VISTA TO TREAT HEMATOLOGIC DISORDERS | Non-Final OA | VANDERBILT UNIVERSITY |
| 17995225 | TOCILIZUMAB FOR THE TREATMENT OF VIRAL INFECTIONS | Non-Final OA | The University of Chicago |
| 18261483 | MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME | Non-Final OA | Washington University |
| 18279938 | ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Non-Final OA | University of Maryland, College Park |
| 17913899 | CLAUDIN-6 TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18257528 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | Non-Final OA | MERUS N.V. |
| 17687909 | MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES | Non-Final OA | Centre National de la Recherche Scientifique (CNRS) |
| 18451216 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS | Non-Final OA | Immatics Biotechnologies GmbH |
| 18031523 | ANTI-LILRB ANTIBODIES AND USES THEREOF | Non-Final OA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) |
| 18036500 | METHODS AND KITS FOR CLASSIFYING SOLID CANCER-AFFLICTED PATIENTS BASED ON RELB LABELLING | Non-Final OA | INSTITUT CURIE |
| 18280712 | CHIMERIC PROTEINS IN AUTOIMMUNITY | Non-Final OA | Shattuck Labs, Inc. |
| 18275142 | BISPECIFIC ANTIBODY | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18270139 | FORMULATION CONTAINING SOLUBLE GP130 DIMER AND METHOD FOR USING SAME | Non-Final OA | I-MAB BIOPHARMA (HANGZHOU) CO., LTD. |
| 18259106 | HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND USES THEREOF | Non-Final OA | Kira Pharmaceuticals (US) LLC |
| 18266540 | NOVEL FRAGMENTED CRS PEPTIDE EXHIBITING IMMUNE ENHANCEMENT ACTIVITY, AND USE THEREOF | Non-Final OA | ZYMEDI CO., LTD. |
| 18255514 | BCMA-TARGETED CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | SHANGHAI ABELZETA LTD |
| 18121075 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN | Non-Final OA | Paracrine Therapeutics AB |
| 17996589 | Polyspecific Binding Molecules and their use in Cell Therapy | Non-Final OA | Innovative Cellular Therapeutics, Inc. |
| 17778382 | ANTI-PD-L1/ANTI-B7-H3 MULTISPECIFIC ANTIBODIES AND USES THEREOF | Non-Final OA | I-MAB |
| 17528714 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | FONDAZIONE IRCCS ISTITUTO NAZIONATE DEI TUMORI |
| 16620275 | T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR | Final Rejection | Region of Southern Denmark |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy